Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Retained Earnings (2017 - 2025)

Dianthus Therapeutics has reported Retained Earnings over the past 8 years, most recently at $163000.0 for Q3 2025.

  • Quarterly results put Retained Earnings at $163000.0 for Q3 2025, up 100.11% from a year ago — trailing twelve months through Sep 2025 was $163000.0 (up 100.11% YoY), and the annual figure for FY2024 was $106000.0, up 125.53%.
  • Retained Earnings for Q3 2025 was $163000.0 at Dianthus Therapeutics, up from -$235.5 million in the prior quarter.
  • Over the last five years, Retained Earnings for DNTH hit a ceiling of $163000.0 in Q3 2025 and a floor of -$431.2 million in Q1 2023.
  • Median Retained Earnings over the past 4 years was -$78.9 million (2022), compared with a mean of -$111.2 million.
  • Biggest five-year swings in Retained Earnings: skyrocketed 129.19% in 2023 and later tumbled 4025833.33% in 2024.
  • Dianthus Therapeutics' Retained Earnings stood at -$161000.0 in 2022, then skyrocketed by 129.19% to $47000.0 in 2023, then soared by 125.53% to $106000.0 in 2024, then surged by 53.77% to $163000.0 in 2025.
  • The last three reported values for Retained Earnings were $163000.0 (Q3 2025), -$235.5 million (Q2 2025), and -$203.9 million (Q1 2025) per Business Quant data.